Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vebicorvir SCHEMBL29485072 | 0.90 | MAPT (0.40) | PKMPOLBKMT2A | |
| Vebicorvir SCHEMBL21250344 | 0.90 | MAPT (0.40) | PKMPOLBKMT2A | |
| Vebicorvir SCHEMBL29366390 | 0.90 | MAPT (0.40) | PKMPOLBKMT2A | |
| SCHEMBL19984571 | 0.86 | POLB (0.35) | PKMBACE1RAB9APOLBKMT2A | |
| SCHEMBL19984755 | 0.85 | TP53 (0.41) | ROCK2RAB9APOLBKMT2ATDP1 | |
| SCHEMBL22746372 | 0.83 | DRD2 (0.37) | PKMBACE1RAB9APOLBKMT2A | |
| SCHEMBL21291403 | 0.81 | PKM (0.37) | ROCK2PKMBACE1RAB9APOLB | |
| SCHEMBL18667100 | 0.81 | ALDH1A1 (0.42) | PKMPOLBKMT2A | |
| SCHEMBL21291308 | 0.80 | EGLN1 (0.40) | ROCK2 | |
| SCHEMBL18667473 | 0.78 | TP53 (0.53) | PKMRAB9APOLBKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | ROCK2 3592/4885PKM 3449/4885BACE1 2172/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | ROCK2 3592/4885PKM 3449/4885BACE1 2172/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | ROCK2 3592/4885PKM 3449/4885BACE1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.